Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab

Transplantation

Volumn 92, Issue 8, 2011, Pages

  Wilson, Colin H ^a,d   Brown, Alison L ^a   White, Steve A ^a   Goodship, Timothy H J ^a,b,c   Sheerin, Neil S ^a   Manas, Derek M ^a  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; COMPLEMENT FACTOR D; DONOR REACTIVE ANTIBODY; ECULIZUMAB; FLUCONAZOLE; HEMOGLOBIN; MEROPENEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRESERVATION SOLUTION; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; CADAVER DONOR; CASE REPORT; COLD ISCHEMIA; COMPLEMENT DEPOSITION; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; FEVER; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT REJECTION; HEMOFILTRATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; LETTER; MAINTENANCE THERAPY; MALE; MYCOSIS; OLIGURIA; PANCREAS GRAFT REJECTION; PLASMAPHERESIS; PRIORITY JOURNAL; REPERFUSION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5A; DIABETIC NEPHROPATHIES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; THROMBOTIC MICROANGIOPATHIES;

EID: 80054767700     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318230c0bd     Document Type: Letter

References (7)

1. Kavanagh D, Goodship T. Haemolytic uraemic syndrome. Nephron Clin Pract 2011; 118: C37.
2. Legendre C, Babu S, Furman R, et al. [SA-FC406] Safety & Efficacy of Eculizumab in aHUS Patients Resistant to Plasma Therapy: Interim Analysis from a Phase II Trial. Denver, Colorado, American Society of Nephrology; 2010.
3. Reynolds JC, Agodoa LY, Yuan CM, et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058.
4. Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006; 19: 789.
5. Schwimmer J, Nadasdy TA, Spitalnik PF, et al. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41: 471.
6. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687.
7. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542.